Tandem Diabetes Care: A Buy Rating Backed by Growth Potential and Valuation Opportunity
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $24
This H.B. Fuller Company Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Tandem Diabetes Care Cut to Equal-Weight From Overweight by Morgan Stanley
Morgan Stanley Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $22
Advisor360° Introduces Tandem: A CRM+ for Independent Financial Advisors
Tandem Diabetes Care Cut to Neutral From Buy by Citigroup
Citi Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $24
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25
Tandem Shares Fall After Downgrades From Wells Fargo, Bernstein
Tandem Diabetes Care Price Target Cut to $24.00/Share From $42.00 by Goldman Sachs
Tandem Diabetes Care Is Maintained at Neutral by Goldman Sachs
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Tandem Diabetes Care Price Target Cut to $22.00/Share From $38.00 by Wells Fargo
Tandem Diabetes Care Cut to Equal-Weight From Overweight by Wells Fargo
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $53
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Price Target Cut to $53.00/Share From $60.00 by Barclays
Tandem Diabetes Care Analyst Ratings
Bernstein Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $25